Introduction: The aim of our study is to evaluate the predictive factors affecting the success of treatment with nephrectomy in patients with poorly functioning kidney and nephrogenic hypertension. Methods: Data for patients who underwent nephrectomy with a diagnosis of nephrogenic hypertension in 3 centers between May 2010 and January 2020 were analyzed. In the postoperative period, if the blood pressure (BP) was below 140/90 mm Hg without medical treatment, it was accepted as complete response; if the arterial BP was below 140/90 mm Hg with medical treatment or less medication, it was accepted as partial response; and if BP did not decrease to normal values, it was accepted as unresponsive. Demographic characteristics, duration of hypertension, preoperative and postoperative BP values, and presence of metabolic syndrome were statistically evaluated. Results: Our study consisted of 91 patients with a mean preoperative hypertension duration of 23.3 ± 12.1 months. Among patients, 42 (46.2%) had complete response, 18 (19.8%) had partial response, and 31 (34.0%) had no response. Preoperative systolic and diastolic BP values were not effective on treatment success (p = 0.071, p = 0.973, respectively), but the increase in age and hypertension duration (p = 0.030 and p < 0.001, respectively) and the presence of metabolic syndrome (p = 0.002) significantly decreased the complete response rates. Conclusions: Preoperative hypertension duration, advanced age, and presence of metabolic syndrome are predictive factors affecting the response to treatment in patients who undergo nephrectomy due to nephrogenic hypertension.

1.
Aydoğdu
S
,
Güler
K
,
Bayram
F
,
Altun
B
,
Derici
Ü
,
Abacı
A
, et al.
[2019 Turkish hypertension consensus report]
.
Turk Kardiyol Dern Ars
.
2019 Sept
;
47
(
6
):
535
46
. .
2.
Omura
M
,
Saito
J
,
Yamaguchi
K
,
Kakuta
Y
,
Nishikawa
T
.
Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan
.
Hypertens Res
.
2004 Mar
;
27
(
3
):
193
202
. .
3.
Rudnick
KV
,
Sackett
DL
,
Hirst
S
,
Holmes
C
.
Hypertension in a family practice
.
Can Med Assoc J
.
1977 Sept 3
;
117
(
5
):
492
7
.
4.
Basiri
A
,
Simforoosh
N
,
Abdi
H
,
Abdi
HR
,
Shahrokhi
SS
,
Hosseini-Moghaddam
SM
.
Role of laparoscopic nephrectomy for management of symptomatic nephrogenic hypertension
.
Urology
.
2007 Sept
;
70
(
3
):
427
30
. .
5.
Lee
SY
,
Lau
H
.
Effectiveness of unilateral nephrectomy for renal hypertension in adults
.
Asian J Surg
.
2008 Oct
;
31
(
4
):
185
90
. .
6.
Goldblatt
H
,
Lynch
J
,
Hanzal
RF
,
Summerville
WW
.
Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia
.
J Exp Med
.
1934 Feb 28
;
59
(
3
):
347
79
.
7.
Johal
NS
,
Kraklau
D
,
Cuckow
PM
.
The role of unilateral nephrectomy in the treatment of nephrogenic hypertension in children
.
BJU Int
.
2005 Jan
;
95
(
1
):
140
2
. .
8.
Troitskiĭ
OA
,
Romanov
VA
.
[Laparoscopic nephrectomy in a patient with a parenchymatous form of nephrogenic hypertension]
.
Urol Nefrol
.
1996 Mar–Apr
(
2
):
8
11
.
9.
Williams
B
,
Mancia
G
,
Spiering
W
,
Agabiti Rosei
E
,
Azizi
M
,
Burnier
M
, et al.
2018 ESC/ESH guidelines for the management of arterial hypertension
.
Eur Heart J
.
2018 Sept 1
;
39
(
33
):
3021
104
. .
10.
Grundy
SM
,
Cleeman
JI
,
Daniels
SR
,
Donato
KA
,
Eckel
RH
,
Franklin
BA
, et al.
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
.
Circulation
.
2005 Oct 25
;
112
(
17
):
2735
52
. .
11.
World Health Organization
.
2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
.
J Hypertens
.
2003
;
21
(
11
):
1983
92
.
12.
Elhage
O
,
Sahai
A
,
Challacombe
B
,
Murphy
D
,
Scoble
J
,
Dasgupta
P
.
Role of laparoscopic nephrectomy for refractory hypertension in poorly functioning kidneys
.
Ann R Coll Surg Engl
.
2011 Jan
;
93
(
1
):
25
6
. .
13.
Campese
VM
,
Mitra
N
,
Sandee
D
.
Hypertension in renal parenchymal disease: why is it so resistant to treatment?
Kidney Int
.
2006 Mar
;
69
(
6
):
967
73
. .
14.
Fonouni
H
,
Mehrabi
A
,
Golriz
M
,
Zeier
M
,
Müller-Stich
BP
,
Schemmer
P
, et al.
Comparison of the laparoscopic versus open live donor nephrectomy: an overview of surgical complications and outcome
.
Langenbecks Arch Surg
.
2014 Jun
;
399
(
5
):
543
51
. .
15.
Shuford
MD
,
McDougall
EM
,
Chang
SS
,
LaFleur
BJ
,
Smith
JA
 Jr
,
Cookson
MS
.
Complications of contemporary radical nephrectomy: comparison of open vs. laparoscopic approach
.
Urol Oncol
.
2004 Mar–Apr
;
22
(
2
):
121
6
. .
16.
Luke
RG
,
Kennedy
AC
,
Briggs
JD
,
Struthers
NW
,
Stirlings
WB
.
Results of nephrectomy in hypertension associated with unilateral renal disease
.
Br Med J
.
1968 Sept 28
;
3
(
5621
):
764
8
. .
17.
Thomaz
MJ
,
Lucon
AM
,
Praxedes
JN
,
Bortolotto
LA
,
Srougi
M
.
The role of nephrectomy of the atrophic kidney in bearers of renovascular hypertension
.
Int Braz J Urol
.
2010 Mar–Apr
;
36
(
2
):
159
70
. .
18.
Gensini
GF
,
Corradi
F
.
[Hypertension as a function of age]
.
Ital Heart J
.
2000 Jun
;
1
(
Suppl 2
):
23
31
.
19.
Leisegang
K
,
Henkel
R
,
Agarwal
A
.
Obesity and metabolic syndrome associated with systemic inflammation and the impact on the male reproductive system
.
Am J Reprod Immunol
.
2019 Nov
;
82
(
5
):
e13178
. .
20.
Samson
SL
,
Garber
AJ
.
Metabolic syndrome
.
Endocrinol Metab Clin North Am
.
2014 Mar
;
43
(
1
):
1
23
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.